Total and LDL cholesterol are associated with glomerular filtration rate in normoalbuminuric type 1 diabetic patients [Ukupni i LDL kolesterol su povezani s glomerularnom flitracijom u normoalbuminuričnih bolesnika sa tipom 1 šećerne bolesti] by Bulum, Tomislav et al.
Coll. Antropol. 37 (2013) 3: 771–776
Original scientific paper
Total and LDL Cholesterol are Associated with
Glomerular Filtration Rate in Normoalbuminuric
Type 1 Diabetic Patients
Tomislav Bulum1, Branko Kolari}2,3, Ingrid Prka~in4 and Lea Duvnjak1
1 University of Zagreb, University Hospital Merkur, »Vuk Vrhovac« Clinic for Diabetes, Endocrinology and Metabolic Diseases,
School of Medicine, Zagreb, Croatia
2 University of Rijeka, School of Medicine, Rijeka, Croatia
3 Zagreb County Institute of Public Health, Zagreb, Croatia
4 University of Zagreb, University Hospital Merkur, School of Medicine, Department of Internal medicine, Zagreb, Croatia
A B S T R A C T
Studies have generally suggested a positive association between dyslipidemia and chronic kidney disease, but sparse
data are available on the relation of lipids and glomerular filtration rate in patients with normal renal function. We in-
vestigated the associations of serum lipids, including total, LDL, HDL, VLDL cholesterol, and triglyceride levels with es-
timated glomerular filtration rate (eGFR) in type 1 diabetic patients. Study included 313 normoalbuminuric type 1 dia-
betic patients with normal or mild decrease (eGFR > 60 mL/min per 1.73 m2) renal function and before any interventions
with statins, ACE inhibitors or angiotensin II receptor blockers. eGFR was significantly associated with total, LDL, and
HDL cholesterol (r= –0.21, –0.18, and –0.17, respectively, for all p <0.05). Stratifying serum lipids for degree of eGFR,
levels of total, LDL, and HDL cholesterol were inversely related to eGFR, but trends were significant only for total (5.1 vs
5.0 and 4.6 mmol/L) and LDL cholesterol (2.9 vs 2.8 and 2.4 mmol/L). We have detected an association between eGFR
and lipid abnormalities in type 1 diabetes in early stages. The study was conducted in patients with no therapeutic inter-
vention. This may suggest that lipid abnormalities may play a role in the pathogenesis of renal impairment in type 1 dia-
betic patients.
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Introduction
Patients with type 1 diabetes have a 20–50% probabil-
ity of developing end-stage renal disease1, and identifica-
tion of the determinants of the onset of early diabetic
nephropathy is essential for reducing the morbidity and
mortality associated with diabetes. In type 1 diabetic pa-
tients many studies have identified poor glycemic control
as a most important risk factor for progression of dia-
betic kidney disease2–4. In addition, other important fac-
tors implicated in the development of nephropathy in-
clude duration of diabetes, smoking and hyperten-
sion2,5,6. Dyslipidemia has also been associated with the
development and progression of nephropathy, and with
mesangial, tubulointerstitial, and glomerular changes in
the kidney7–9. Studies have suggested a positive associa-
tion between dyslipidemia and advanced chronic kidney
failure, but the relation between these markers and nor-
mal or mild renal dysfunction has not been well investi-
gated. Moreover, it was postulated that lipids mainly act
as late-stage accelerators or precipitators of nephropathy
rather than underlying etiologic factor in type 1 diabe-
tes10.
In type 1 diabetic patients, although mortality from
cardiovascular disease is three- to sixfold that of the gen-
eral population11, total, low density lipoprotein (LDL)
cholesterol and triglyceride levels are usually within the
normal range, and high density lipoprotein (HDL) cho-
lesterol levels are also normal or even elevated12,13. How-
ever, multiple lipid abnormalities are present in early
stages of diabetic nephropathy in type 1 diabetic pa-
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tients, even in state of normal or elevated glomerular fil-
tration rate (GFR)14,15. In a number of studies, an in-
crease in total and LDL cholesterol levels has been found
to be a risk factor for nephropathy in type 1 diabetes2,7,8,
16–18. Moreover, it was found that in those subjects with
total cholesterol over 7 mmol/L the rate of decline in
GFR was at least three times higher than in those with a
level below 7 mmol/L19. In addition, in patients with dia-
betic nephropathy the diameter of LDL particles has
been reported to be smaller as compared to diabetic pa-
tients without nephropathy20.
Little is known about the relationship between lipids
and change in renal function among individuals with
normal renal function, because most studies have fo-
cused on the progression of established renal disease.
The objective of this study, therefore, was to evaluate the
associations of serum lipids, including total, LDL, HDL,
VLDL cholesterol and triglyceride levels with estimated
GFR (eGFR) in normoalbuminuric type 1 diabetic pa-
tients with eGFR > 60 mL min–1 1.73 m–2.
Subjects, Materials And Methods
This study included 313 euthyroid patients with dia-
betes mellitus type 1. Type 1 diabetes was defined as an
onset of diabetes before the age of 35 years, positive
autoantibodies and permanent insulin treatment initi-
ated within 1 year of diagnosis. The study included pa-
tients following characteristics: age of 18–65 years, mini-
mum duration of type 1 diabetes of 1 year, no medical
history of cardiovascular diseases or electrocardiogram
(ECG) evidence of ischemic heart disease, absence of any
systemic disease, and absence of any infections in the
previous month. Patients with chronic renal disease or
other chronic diseases likely to affect renal function were
excluded. Patients were excluded from the study if they
had taken any of the following: lipid-lowering therapy,
antihypertensive therapy including ACE inhibitor or an-
giotensin II receptor blockers, medications that might af-
fect glucose metabolism such as glucocorticoids as well as
patients taking oral glucose-lowering medication. Acute
and chronic inflammation was excluded on the basis of
medical history, physical examination, and routine labo-
ratory tests, including measurement of temperature and
urinalysis.
All subjects were studied in the morning after an
overnight fast. Basic anthropometric measurements we-
re performed on all study subjects. Waist to hip ratio was
calculated from the waist circumference (measured on
bare skin as the narrowest circumference between the
10th rib and the iliac crest with tailor meter) and hip cir-
cumference (at the widest point of the gluteal muscles)
and expressed in centimeters. Weight was measured by
the physician using a balanced-beam scale with light
clothing without shoes and expressed in kilograms (kg).
Height was measured using a wall mounted stadiometer
and expressed in centimeters (cm). Body mass index
(BMI) was calculated as weight in kilograms divided by
the square of height in meters (kg/m2). Blood pressure
was measured twice in the sitting position with a mer-
cury sphygmomanometer after a resting period of 10
minutes and expressed in mmHg. UAE was measured
from at least two 24-h urine samples and determined as
the mean of 24-h urine collections. Patients performed
collections on two consecutive days to minimize variabil-
ity. Normoalbuminuria was defined as a UAE<30mg/24 h.
Those with microalbuminuria (UAE ³30<300 mg/24 h)
and macroalbuminuria (UAE ³300 mg/24 h) were ex-
cluded from the study. Serum creatinine was measured
in fasting blood sample. From 2011 creatinine was mea-
sured by an enzymatic method that produced values
traceable to the isotope dilution mass spectrometry
(IDMS) values. We calibrated creatinine results gener-
ated before 2011 to the IDMS-traceable values obtained
with the enzymatic method. Data on serum creatinine
levels, age, sex and race were used to calculate the esti-
mated glomerular filtration rate (eGFR) using the Chro-
nic Kidney Disease Epidemiology Collaboration (CKD-
-EPI) formula and Modification of Diet in Renal Disease
formula (MDRD)21. Renal function was further estima-
ted using the Cockcroft-Gault formula for creatinine
clearance adjusted for body surface area, which has been
shown to be as accurate as creatinine clearance mea-
sured by 24 hour urine collections in diabetics22. Crea-
tinine clearance >90 mL/min per 1.73 m2was considered
normal, 60–90 mL/min per 1.73 m2 was considered a mild
decrease, and those with creatinine clearance <60 mL/
min per 1.73 m2, who has moderate to severe renal im-
pairment, were excluded from the study23.
Fasting venous blood samples were collected in the
morning between 08:00 and 09:30 hours after an over-
night fast for the determination of HbA1c, total, LDL,
HDL, VLDL cholesterol, triglycerides and fasting glu-
cose. Microalbumin and HbA1c was measured spectro-
photometrically by turbidimetric immuno-inhibition
(Olympus AU600, Beckman-Coulter, USA). Results of
HbA1c (%) are expressed in the DCCT-equivalent. Glu-
cose, cholesterol and triglycerides in serum were mea-
sured by an enzymatic colorimetric method, after precip-
itation with polyethylene glycol on an automatic spectro-
photometer (Olympus AU600, Beckman-Coulter, USA).
Complete blood count was determined on an automatic
blood counter (Advia 120, Siemens Diagnostic Solutions,
USA).
The study protocol complies with the Declaration of
Helsinki as well as with local institutional guidelines,
and was approved by the local ethnics committees.
Data are expressed as means ± SD for normally dis-
tributed values, as median with range for non-normally
distributed values, and percentage. Correlations between
parameters of renal function with anthropometric and
metabolic variables were determined using Spearman
rho test. To investigate the relation between serum lipids
with GFR data were also stratified in different groups of
GFR. Kruskal-Wallis test was used for calculating the
significance of the trend for each variable among the dif-
ferent groups. Multiple logistic regression analysis was
used to assess associations of serum lipids with risk of
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lower eGFR. Level of statistical significance was chosen
to á=0.05. Statistical analysis was performed by statisti-
cal package STATA/IC ver.11.1.
Results
The characteristics of the study subjects are listed in
Table 1. The average age was approximately 34 years,
most were not overweight and 51% of subjects were fe-
male. Mean/median values of BMI, waist to hip ratio
(WHR), systolic and diastolic blood pressure, fasting glu-
cose, HDL cholesterol, and triglycerides were within the
normal range for patients with diabetes with slightly ele-
vated levels of HbA1c, total and LDL cholesterol. The
majority of patients had high HDL cholesterol (for men
³1.0 mmol/L, 96% of patients; for women ³1.3 mmol/L,
95% of patients). The mean GFR estimated by the
CKD-EPI was 106 mL min–1 1.73 m–2. The mean esti-
mated GFR of 96 mL min–1 1.73 m–2 estimated using
MDRD formula and Cockcroft-Gault formula was signifi-
cantly lower than when estimated using the CKD-EPI
formula.
Associations of eGFR with anthropometric and meta-
bolic variables are presented in Table 2. GFR estimated
using the CKD-EPI formula was significantly associated
with duration of diabetes, fasting glucose, daily insulin
dose, HbA1c, total, LDL, and HDL cholesterol, with du-
ration of diabetes, total and HDL cholesterol showing the
strongest correlation (r= –0.29, –0.21, and –0.21, respec-
tively, all p<0.05). Similar correlation results were found
between anthropometric and metabolic variables and
GFR estimated using the MDRD formula. GFR esti-
mated using the Cockcroft-Gault formula was signifi-
cantly correlated with even 10 parameters (duration of
diabetes, BMI, WHR, fasting glucose, daily insulin dose,
total, LDL, HDL, VLDL cholesterol and diastolic blood
pressure) with BMI and WHR showing the strongest cor-
relation (r=0.34, and –0.30, all p<0.05).
Relationship between eGFR among patients with a
mild decrease of renal function, normal renal function and
hyperfiltrating patients are presented in Table 3. Strat-
ifying serum lipids for degree of GFR, estimated using
the CKD-EPI formula, levels of total, LDL, and HDL
cholesterol were inversely related to eGFR, but trends
were significant only for total and LDL cholesterol. In
addition, those patients with eGFR  90 mL/min/1.73 m2
were older, had longer duration of diabetes and higher
daily insulin dose, but lower HbA1c.
In logistic regression analysis, higher total, LDL and
HDL cholesterol was significantly associated with risk of
lower eGFR estimated with CKD-EPI formula (OR=
0.49–0.65, p=0.001) (Table 4, Model A). However, after
adjustment for age, sex and duration of diabetes serum
lipids were not associated with eGFR in our normoalbu-
minuric subjects (Table 4, Model B).
Discussion
Serum lipids may play a significant independent role
in the development of diabetic nephropathy and decline
in renal function and progression of albuminuria2,7–9,
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TABLE 1
CLINICAL AND METABOLIC CHARACTERISTICS
OF ALL PATIENTS
Variable
mean Interquartile
± SD range
Age (years) 35±10 18–65
Duration of diabetes (years) 13±9 1–42
Body mass index (kg/m2) 24±3 15–37
Waist to hip ratio 0.81±0.07 0.6–1.0
Fasting glucose (mmol/L) 5.7±2.0 2.7–10.2
HbA1c (%) 7.43±1.63 4.5–14.2
Daily insulin dose (IU/d) 42±14 8–96
Systolic blood pressure (mmHg) 122±14 79–180
Diastolic blood pressure (mmHg) 78±9 50–100
Total cholesterol (mmol/L) 5.0±0.8 2.5–7.8
LDL cholesterol (mmol/L) 2.8±0.7 0.6–4.9
HDL cholesterol (mmol/L) 1.7±0.4 0.7–3.0
VLDL cholesterol (mmol/L) 0.48±0.29 0.16–1.9
Triglycerides (mmol/L) 1.07±0.6 0.3–4.1
Serum creatinine (mmol/L) 71±14 39–138
CKD-EPI (mL min–1 1.73 m–2) 106±16 60–143
MDRD (mL min–1 1.73 m–2) 96±20 52–171
Cockcroft-Gault (mL min–1 1.73 m–2) 96±24 47–211
Urinary albumin excretion (mg/24 h) 12.5±7.2 1.7–29.8
CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration,
MDRD – Modification of Diet in Renal Disease.
TABLE 2
SPEARMAN CORRELATION ANALYSIS OF ASSOCIATIONS OF
EGFR WITH METABOLIC AND ANTHROPOMETRIC VARIABLES
Variable CKD-EPI MDRD Cockcroft-
-Gault
Age –0.60* –0.42* –0.52*
Duration of diabetes –0.29* –0.21* –0.27*
Body mass index –0.10 –0.13* 0.34*
Waist to hip ratio 0.01 0.01 0.30*
Fasting glucose –0.13* –0.12* –0.11*
HbA1c 0.15* 0.18* 0.10
Daily insulin dose 0.13* 0.11* 0.25*
Total cholesterol –0.21* –0.18* –0.17*
LDL cholesterol –0.18* –0.15* –0.12*
HDL cholesterol –0.17* –0.16* –0.28*
VLDL cholesterol 0.06 0.06 0.15*
Triglycerides 0.06 0.06 0.15*
Systolic blood pressure –0.08 –0.07 0.07
Diastolic blood pressure –0.01 –0.01 0.12*
* p<0.05, CKD-EPI – Chronic Kidney Disease Epidemiology
Collaboration, MDRD – Modification of Diet in Renal Disease.
14–18,24,25. In a number of studies, an increase in total and
LDL cholesterol levels has been found to be a risk factor
for nephropathy in type 1 diabetes2,7,8,16–18. In this cross-
-sectional study of 313 normoalbuminuric type 1 diabetic
patients with normal renal function we demonstrated
that lipid profiles of patients with type 1 diabetes are not
only closely related to albuminuria, but also to estimated
GFR.
It has been argued that in type 1 diabetes increased
HbA1c as a marker of chronic hyperglycemia is the most
important risk factor for progression of diabetic kidney
disease2–4,26. Hyperglycemia also leads to glycation of
lipids and lipoproteins in diabetic patients that may slow
down the catabolism of atherogenic LDL-cholesterol27.
However, mean HbA1c levels (7.4%) in our subjects was
significantly lower than in most previous studies and our
subjects with mild decrease of renal function and higher
LDL cholesterol had, surprisingly, significantly lower
levels of HbA1c compared to subjects with higher eGFR.
Hyperlipidemia contributes not only to cardiovascu-
lar disease but also to renal disease progression28. In
both type 1 and type 2 diabetes an unfavorable lipid pro-
file is present at a very early stage of albuminuria, even
when GFR is normal or elevated29,30. It was also demon-
strated that both total and LDL cholesterol measured at
baseline were associated with significantly higher inci-
dence of microalbuminuria, end stage renal disease as
well as of cardiovascular events in patients with type 2
diabetes18,31,32. Our patients with estimated GFR 60–90
mL min–1 1.73 m–2 display an atherogenic lipid profile
with high total cholesterol and LDL cholesterol. Circu-
lating lipoproteins play a direct role in the pathogenesis
of glomerulosclerosis and tubulointerstitial changes7–9,33.
Animal models suggest that dyslipidemia plays an impor-
tant role not only in the progression of chronic renal dis-
ease but also in its development34. In addition, a decline
in renal function has been reported to be associated with
advanced glomerular lesions even in normoalbuminuric
type 1 diabetic patients with reduced GFR35. Combined
angiotensin-converting enzyme inhibitor and statin the-
rapy limited glomerulosclerosis, tubular damage, and in-
terstitial inflammation with a significant improvement
in renal function36,37. Our study included patients before
any interventions with statins, ACE inhibitors or angio-
tensin II receptor blockers that may allows purer physio-
logical examination of the association between GFR and
serum lipids because ACE-inhibitors can elevate serum
creatinine and statins lower serum lipids. However, it
should be stressed that associations between lipid abnor-
malities and renal function in our study is weak, and that
associations were lost in multivariate analysis.
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TABLE 3
LEVELS OF SERUM LIPIDS DEPENDING ON LEVEL OF EGFR (ESTIMATED WITH THE CKD-EPI FORMULA)
Variable eGFR 60–89 eGFR 90–120 eGFR ³120 P
mL min–1 1.73 m–2
N 55/313 220/313 38/313
Sex (m/f) 19/36 116/104 17/21 0.04
Age (years) 45 (19–60) 35 (19–65) 22 (18–34) <0.001
Duration of diabetes (years) 16 (2–42) 12 (1–42) 7 (1–25) <0.001
Body mass index (kg/m2) 24 (17–33) 24 (17–37) 24 (15–34) 0.4
Waist to hip ratio 0.81±0.07 0.81±0.06 0.81±0.06 0.7
HbA1c (%) 7.1±1.2 7.3±1.6 8.4±1.9 0.002
Fasting glucosae (mmol/L) 5.5 (2.4–12.6) 5.4 (2.2–12.5) 4.7 (2.1–9.1) 0.1
Daily insulin dose (IU/d) 47±15 42±14 39±11 0.02
Systolic blood pressure (mmHg) 120 (79–170) 120 (90–180) 120 (90–140) 0.3
Diastolic blood pressure (mmHg) 80 (65–110) 80 (60–110) 80 (50–90) 0.7
Total cholesterol (mmol/L) 5.1±0.7 5.0±0.9 4.6±0.7 0.02
LDL cholesterol (mmol/L) 2.9±0.7 2.8±0.7 2.4±0.7 0.006
HDL cholesterol (mmol/L) 1.8±0.4 1.6±0.3 1.6±0.3 0.1
VLDL cholesterol (mmol/L) 0.41 (0.2–1.15) 0.40 (0.16–1.9) 0.43 (0.2–1.89) 0.3
Triglycerides (mmol/L) 0.91 (0.4–2.5) 0.8 (0.3–4.1) 0.95 (0.4–4.1) 0.3
TABLE 4
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF SERUM
LIPIDS WITH DEVELOPMENT OF LOWER EGFR (ESTIMATED
WITH THE CKD-EPI FORMULA)
Independent Model A Model B
variable
Total cholesterol 0.65 (0.50–0.84)* 1.01 (0.73–1.38)
LDL cholesterol 0.60 (0.44–0.82)* 0.93 (0.64–1.35)
HDL cholesterol 0.49 (0.28–0.87)* 0.96 (0.46–1.99)
VLDL cholesterol 1.53 (0.71–3.29) 1.52 (0.60–3.83)
Triglycerides 1.20 (0.85–1.70) 1.20 (0.79–1.82)
Data are OR (95% CI) from separate models. Model A crude;
model B adjusted for age, sex and duration of diabetes.
* p<0.05.
It is also possible that insulin resistance syndrome
may underlie or mediate the association between lipids
and a loss of renal function because insulin resistance in
patients with type 1 diabetes underlies many of the alter-
ations of diabetic nephropathy including serum lipids38,39.
Our patients with mild decrease of renal function have
higher daily insulin dose in contrast to subjects who had
normal or elevated renal function suggesting that insulin
resistance through associated dyslipidemia may play a
role in the diabetic nephropathy.
The present study has a number of potential limita-
tions. First, we did not measured GFR directly. However,
there is no optimal non-invasive method to estimate
early changes in renal function and radio-isotope clear-
ance GFRmeasurements are impractical for this number
of patients. The MDRD formula tends to overestimate
the number of patients with impaired renal function21,
Cockcroft-Gault formula overestimates the actual renal
function, while CKD-EPI formula has been shown to be
accurate in determining renal function in diabetic pa-
tients with normal renal function40. Second, our study
was cross-sectional, which limited our ability to infer a
causal relation between serum lipids and risk of ne-
phropathy. Third, our analyses were based on measure-
ment of traditional lipoprotein markers. However, it is
likely that in clinical practice the measurement of con-
ventional lipoprotein parameters is sufficient to assess
the risk of microvascular complications in type 1 diabe-
tes, in contrast to additional parameters which make lit-
tle predictive impact16. Fourth, our analyses were based
on measurement of serum creatinine, eGFR and urinary
albumin excretion on two consecutive days that may not
reflect the relation over time. Prospective studies are
needed to evaluate whether the observed lipid abnormal-
ities play a role in the progression of renal function in
type 1 diabetic patients.
In conclusion, we have detected an association be-
tween eGFR and lipid abnormalities in type 1 diabetes in
early stages. The study was conducted in patients with
no therapeutic intervention. This may suggest that lipid
abnormalities may play a role in the pathogenesis of re-
nal impairment in type 1 diabetic patients.
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UKUPNI I LDL KOLESTEROL SU POVEZANI S GLOMERULARNOM FILTRACIJOM U
NORMOALBUMINURI^NIH BOLESNIKA SA TIPOM 1 [E]ERNE BOLESTI
S A @ E T A K
Mnoga istra`ivanja su potvrdila zna~aj dislipidemije u kroni~noj bubre`noj bolesti, ali malo toga je poznato o utje-
caju serumskih lipida na glomerularnu filtraciju u osoba sa normalnom bubre`nom funkcijom. Istra`ivali smo poveza-
nost serumskih lipida (ukupnog, LDL, HDL, HDL2, HDL3, VLDL kolesterola i triglicerida) te glomerularne filtracije
(GF) u bolesnika sa tipom 1 {e}erne bolesti. Istra`ivanje je obuhvatilo 313 normoalbuminuri~nih bolesnika sa tipom 1
{e}erne bolesti s urednom ili blago sni`enom bubre`nom funkcijom (GF >60 mL/min/ 1.73 m2) i prije terapije sta-
tinima, ACE-inhibitorima ili blokatorima angiotenzinskih receptora. GF procijenjena CKD-EPI i MDRD formulom bila
je statisti~ki zna~ajno povezana s ukupnim, LDL, HDL, HDL2, i HDL3 kolesterolom (r= –0.21, –0.18, –0.17, –0.21, i
–0.14, za sve p<0.05). Nakon podjele bolesnika prema stupnju GF, razina ukupnog, LDL, HDL i HDL2 kolesterola je
bila u negativnoj povezanosti s razinom GF, ali je statisti~ki zna~ajna povezanost dokazana samo za razinu ukupnog
(5.1 prema 5.0 i 4.6 mmol/L) i LDL kolesterola (2.9 prema 2.8 i 2.4 mmol/L). Rezultati istra`ivanja ukazuju da je lipidni
poreme}aj prisutan ve} u stanju normalne bubre`ne funkcije u normoalbuminuri~nih bolesnika sa tipom 1 {e}erne
bolesti i da je vi{a razina ukupnog i LDL kolesterola povezana s pogor{anjem GF. Prospektivne studije }e pokazati da li
navedeni lipidni poreme}aji doprinose progresiji bubre`ne bolesti u bolesnika sa tipom 1 {e}erne bolesti.
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